The GAMMA-MRI project has gone significantly beyond the state of the art by developing a modality that records a single type of signal with the high spatial resolution of Magnetic Resonance Imaging (MRI), the high sensitivity of Positron Emission Tomography (PET), and the simplicity of Single Photon Emission Computed Tomography (SPECT). Through this approach, sub-millimetre resolution images have been obtained using only nano to pico molar concentrations of tracer, by means of gamma detectors integrated within a low-field MRI magnet. The project demonstrated that hyperpolarisation of gamma-emitting nuclei induces asymmetric gamma emission, and that MRI sequences can depolarise nuclei leading to measurable changes in gamma asymmetry. This technique has proven to be several orders of magnitude more sensitive than traditional RF signal detection in conventional MRI.
Our work has provided European leaders in science and technology with a unique competitive advantage in developing next-generation imaging modalities, applicable in preclinical and clinical settings for multi-tracer, real-time, high-speed, and high-sensitivity studies.
During the course of the project, several critical science-to-technology breakthroughs were accomplished:
- Efficient hyperpolarisation of metastable xenon isotopes (mXe) through Spin Exchange Optical Pumping (SEOP).
- Successful storage and transport of Hyperpolarized gamma-emitting tracers, enabling the separation of hyperpolarisation and imaging phases.
- Development of fast, compact, high-sensitivity gamma detectors compatible with magnetic fields and capable of high count rates.
- Development of advanced data acquisition strategies, including compressed sensing methods.
The project also delivered a low-field prototype GAMMA-MRI device, which successfully combined all these technological advances. Tests using 1H and 129Xe MRI, along with gamma-asymmetry detection experiments, demonstrated the technique's potential for revolutionary in vitro and possibly in vivo imaging applications.
GAMMA-MRI offers major advantages for healthcare: reduced device cost (estimated under €100,000), portability, enhanced safety through lower magnetic fields, and improved accessibility to molecular imaging at the point-of-care. Initially focused on brain perfusion and stroke diagnosis, the technology is adaptable to other organs and clinical applications. The project’s results are expected to create new jobs in the imaging and medical technology sectors, and to contribute significantly to budget savings in European healthcare systems by shifting towards simpler, more affordable imaging devices.